BioCon Biologics
BioCon Biologics offers the My BioCon Biologics program to provide continuous access and support to patients who have been prescribed Fulphila or Ogivri (Table).
Co-pay Assistance Program
With My BioCon Biologics, commercially insured patients may be able to access Fulphila for as little as $0 copay up to a maximum of $10,000 per 12-month period and Ogivri for as little as $0 copay up to a maximum of $25,000 per 12-month period.
Patient Assistance Program
Patients without insurance coverage for Fulphila or Ogivri who cannot afford their medication may be able to receive their medication free of charge. Contact Viatris Advocate at My BioCon Biologics for more information.
TABLE BioCon Biologics Oncology/Supportive Care Drugs
Drug
Indications
Patient support programs
Drug
Fulphila (pegfilgrastim-jmdb)
Indications
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Patient support programs
Drug
Ogivri (trastuzumab-dkst)
Indications
Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product
Patient support programs